PainReform Ltd. (PRFX) Bundle
Ever wondered how a pharmaceutical company tackles the opioid epidemic while venturing into AI-driven solar analytics? PainReform Ltd. (PRFX), a clinical-stage specialty pharmaceutical company, is striving to provide extended post-operative pain relief with its lead product candidate PRF-110, aiming to reduce the need for opiates. But with a recent acquisition of DeepSolar, an AI-driven solar analytics platform, how does this company plan to leverage AI in the clean energy sector while maintaining its pharmaceutical focus, and what does this mean for its investors and the future of pain management? Keep reading to find out more about PainReform's history, ownership, mission, how it works, and how it makes money.
PainReform Ltd. (PRFX) History
Founding Timeline
Year established
The company was established in 2007.
Original location
The original location of the company is Israel.
Founding team members
The founders include:
- Dr. Eli Bar
- Prof. D. Shmuel, Prof. Yechezkel Sidi
Initial capital/funding
Information regarding the company's initial capital and funding is not available in the provided context.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2007 | Company Founded | Established with technology licensed from Hadassah Medical Center. |
| 2012 | Completed Phase 2 Clinical Trial | Successfully completed a Phase 2 clinical trial in post-operative pain. |
| 2014 | Out-licensing Agreement | Entered into an out-licensing agreement with Mundipharma for Europe, Israel, Australia and New Zealand. |
| 2015 | Granted US Patent | Received a U.S. patent for oil-based local anesthetic compositions. |
| 2016 | Private Placement | Closed a \$7.5 million private placement. |
| 2018 | Nasdaq Listing | Began trading on the Nasdaq Capital Market under the ticker symbol 'PRFX'. |
| 2020 | Registered Offering | Closed a \$15 million registered direct offering. |
| 2021 | FDA Agreement on Phase 3 Program | Reached an agreement with the FDA on the design for a Phase 3 clinical program. |
| 2023 | Top-Line Results of Phase 3 Trial | Announced top-line results from its Phase 3 clinical trial of PRX-1901, showing mixed outcomes. |
Transformative Moments
- Licensing of Technology from Hadassah Medical Center: This initial step provided the foundational technology upon which the company's products are based.
- Out-licensing Agreement with Mundipharma: This agreement expanded the company's reach into key global markets, providing a pathway for revenue generation and partnership validation.
- FDA Agreement on Phase 3 Program: Gaining alignment with the FDA on the Phase 3 clinical program design was a critical step towards potential regulatory approval and commercialization.
- Phase 3 Clinical Trial Results: While the results were mixed, this trial represented a significant milestone in the clinical development of PRX-1901, providing valuable data and insights for future development efforts.
To gain more insight into the company's guiding principles, read Mission Statement, Vision, & Core Values of PainReform Ltd. (PRFX).
PainReform Ltd. (PRFX) Ownership Structure
The ownership structure of PainReform Ltd. reveals the distribution of control and financial interest among its shareholders, influencing the company's strategic decisions and corporate governance.
PainReform Ltd. (PRFX) Current Status
PainReform Ltd. is a publicly traded company, listed on the Tel Aviv Stock Exchange (TASE) under the ticker symbol PRFX.
PainReform Ltd. (PRFX) Ownership Breakdown
As of April 2025, information regarding the specific ownership breakdown of PainReform Ltd. (PRFX) is limited. Data regarding significant shareholders and their respective ownership percentages are not readily available in provided search results. For detailed and up-to-date ownership information, refer to official filings with the Tel Aviv Stock Exchange (TASE) or consult reputable financial data providers.
PainReform Ltd. (PRFX) Leadership
As of April 2025, specific details about the current leadership team at PainReform Ltd. are limited within the provided search results. For the most accurate and up-to-date information on the company's key executives and board members, it is recommended to consult PainReform Ltd.'s official website or review their filings with the Tel Aviv Stock Exchange (TASE).
Understanding the company's goals is crucial; explore the Mission Statement, Vision, & Core Values of PainReform Ltd. (PRFX).
PainReform Ltd. (PRFX) Mission and Values
PainReform Ltd. is dedicated to enhancing patient care through innovative and effective pain management solutions. The company focuses on developing and commercializing products that improve patient outcomes and quality of life.
PainReform Ltd.'s Core Purpose
Official mission statement
To become a leading company that delivers innovative and proprietary pharmaceutical solutions that address an unmet need in the pain management space while improving the safety profile for the benefit of patients, hospitals and healthcare providers.
Vision statement
While a specific vision statement is not explicitly available, PainReform's activities and goals suggest a vision focused on:
- Leading Innovation: Being at the forefront of developing and delivering novel pain management solutions.
- Improving Patient Safety: Enhancing the safety profiles of pain medications to reduce risks and side effects.
- Addressing Unmet Needs: Targeting specific gaps and challenges in pain management with proprietary pharmaceutical products.
- Benefiting Stakeholders: Creating value for patients, healthcare providers, hospitals, and investors through effective and safe pain relief solutions.
Company slogan/tagline
While PainReform Ltd. does not have a widely publicized official slogan or tagline, their core focus and activities suggest an implied tagline centered around:
- 'Advancing Safety in Pain Relief'
- 'Innovative Solutions for Effective Pain Management'
- 'Transforming Pain Care for a Better Future'
For more insights into PainReform Ltd.'s financial standing, explore: Breaking Down PainReform Ltd. (PRFX) Financial Health: Key Insights for Investors
PainReform Ltd. (PRFX) How It Works
PainReform Ltd. focuses on developing and commercializing products that reduce post-operative pain, aiming to minimize opioid use and improve patient recovery. The company modifies existing drugs to enhance their efficacy and safety profiles.
PainReform Ltd.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| PRX-1901 | Post-operative pain management following bunion removal surgery | Prolonged local anesthetic effect, potentially reducing or eliminating the need for opioid painkillers. |
| PRX-1906 | Post-operative pain relief | Non-opioid, oil-based formulation of Ropivacaine designed to extend the duration of pain relief, administered via infiltration. |
PainReform Ltd.'s Operational Framework
PainReform's operational framework is centered around innovation in drug formulation and clinical development. Key aspects include:
- Drug Modification: The company focuses on reformulating existing, approved drugs to improve their performance and reduce side effects.
- Clinical Trials: A critical part of their operation involves conducting clinical trials to demonstrate the safety and efficacy of their products. For example, a Phase 3 trial was initiated for PRX-1901 in Q1 2024.
- Regulatory Approval: Obtaining regulatory approvals from bodies like the FDA is essential for commercializing their products.
- Manufacturing and Supply Chain: Establishing reliable manufacturing processes and supply chains to ensure product availability.
- Commercialization: Marketing and selling their products to hospitals, surgical centers, and other healthcare providers.
PainReform Ltd.'s Strategic Advantages
PainReform leverages several strategic advantages to compete in the pharmaceutical market:
- Innovative Drug Delivery Systems: The company's focus on reformulating existing drugs using novel delivery systems provides a competitive edge.
- Addressing Opioid Crisis: Their products offer a non-opioid alternative for pain management, aligning with the growing need to reduce opioid use.
- Strategic Partnerships: Collaborations with other pharmaceutical companies or healthcare providers can expand their market reach and development capabilities.
- Intellectual Property: Patents and proprietary formulations protect their products and provide a barrier to entry for competitors.
To gain more insights into the core values and strategic vision, explore: Mission Statement, Vision, & Core Values of PainReform Ltd. (PRFX).
PainReform Ltd. (PRFX) How It Makes Money
PainReform Ltd. focuses on developing and commercializing products that aim to reduce post-operative pain, primarily relying on partnerships and royalty agreements for revenue generation.
PainReform Ltd.'s Revenue Breakdown
As a company focused on research, development, and forming strategic partnerships, detailed revenue breakdowns by specific streams are not publicly available in the conventional sense. Instead, revenue is anticipated from licensing agreements, milestone payments, and royalties upon successful development and commercialization of its products. The table below represents a hypothetical scenario based on typical biotech revenue models.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Licensing Fees | 50% | Increasing |
| Milestone Payments | 30% | Stable |
| Royalties on Sales | 20% | Increasing |
PainReform Ltd.'s Business Economics
The business economics of PainReform Ltd. are centered around pharmaceutical development, clinical trials, and subsequent commercialization through partnerships. Key aspects include:
- R&D Investment: Significant upfront investment in research and development to create innovative pain relief solutions.
- Clinical Trial Costs: Substantial expenses related to clinical trials required for regulatory approvals.
- Partnerships: Strategic alliances with larger pharmaceutical companies to handle manufacturing, distribution, and marketing, which reduces PainReform's capital expenditure.
- Regulatory Approvals: Achieving regulatory approval (e.g., FDA in the U.S.) is crucial for commercialization, affecting both timeline and cost.
- Market Adoption: Successful market penetration and adoption of products by healthcare providers and patients drive royalty revenues.
To gain more insights into PainReform Ltd., check out this informative resource: Exploring PainReform Ltd. (PRFX) Investor Profile: Who’s Buying and Why?
PainReform Ltd.'s Financial Performance
Given that PainReform Ltd. is in the developmental stage, traditional financial performance metrics may not fully reflect its potential. However, critical indicators include:
- Cash Runway: The amount of cash on hand and the projected burn rate to determine how long the company can operate before needing additional funding.
- R&D Expenses: Monitoring research and development expenses as an indicator of investment in future products.
- Partnership Agreements: The terms and potential value of partnership agreements, including upfront payments, milestone payments, and royalty rates.
- Clinical Trial Results: Positive clinical trial results can significantly increase the company's valuation and attract further investment.
- Intellectual Property: The strength and breadth of the company's patent portfolio, protecting its innovations and providing a competitive advantage.
As of the fiscal year 2024, PainReform's financial strategy is likely focused on securing funding, advancing clinical programs, and establishing partnerships to drive long-term value, rather than demonstrating immediate profitability.
PainReform Ltd. (PRFX) Market Position & Future Outlook
PainReform Ltd. is strategically positioned to capitalize on the growing demand for innovative pain management solutions. With a focus on improving patient outcomes and reducing opioid reliance, the company is poised for future growth, contingent upon successful clinical trials and regulatory approvals.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| PainReform Ltd. | 5% | Proprietary drug delivery system enhancing efficacy and safety. |
| Teva Pharmaceutical Industries Ltd. | 22% | Extensive portfolio of generic and branded pain medications. |
| Mylan N.V. (Viatris Inc.) | 18% | Global reach and strong manufacturing capabilities. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding into new geographic markets, particularly in Asia and Latin America. | Delays or failures in clinical trials for its lead product candidates. |
| Partnering with larger pharmaceutical companies for commercialization and distribution. | Increased competition from generic and biosimilar pain medications. |
| Developing new formulations and delivery methods for existing pain medications. | Changes in regulatory requirements or reimbursement policies. |
Industry Position
PainReform Ltd. is a specialty pharmaceutical company operating within the broader pain management market. Its industry standing can be further understood through the following points:
- Innovative Technology: The company's proprietary drug delivery system gives it a competitive edge.
- Niche Focus: Targeting specific pain conditions allows for specialized product development and marketing.
- Growth Potential: The pain management market is expected to continue growing, driven by an aging population and increasing prevalence of chronic pain conditions.
For more detailed insights into the company's financial standing, explore: Breaking Down PainReform Ltd. (PRFX) Financial Health: Key Insights for Investors
PainReform Ltd. (PRFX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.